Interleukin-12 (IL-12) Validated as a Potent Immunotherapy
-
Proinflammatory cytokine that plays roles in innate & adaptive immunity
- Enhances natural killer & CD8+ T cells cytotoxic activity
- Induces an IFN-gamma-dominated CD4+ T cell response
-
Extensive pre-clinical & clinical evidence shows IL-12 efficacy against multiple tumor types
- Previous development stopped due to toxicity & pharmacokinetics, issues Neumedicines overcomes with their IL-12 (HemaMax)
-
HemaMax synergistic when combined with standard of care (SOC)
- Clinical data suggests tumor antigens generated by cytotoxic cancer treatments, including checkpoint inhibitors, drive IL-12’s adaptive immune response
Pleotropic Effects Ensure Durable, Complete Responses in Multiple Tumor Types
Hematopoiesis
-
Stem cell factor & multi-Lineage cell regeneration
- →
-
Total cell replenishment Reduces toxicity
Innate Immunity
-
Cytotoxic NK cell activation
- →
-
Tumor cell killing
Antigen Presentation
-
Dendritic cell activation & tumor antigen processing
- →
-
IL-12 production T cell activation
Adaptive Immunity
-
CD4 + Th1 cell activation
- →
-
IFN production
-
CD8+ activation
- →
-
Pro-inflammatory
-
B cell activation
- →
-
Tumor cell killing
-
Decreased MDSC & Tregs
- →
-
Decreased immune-suppression
-
Generation of Immune Memory
- →
-
Antibody generation
Chemokine release
Cell Migration
-
Chemokine (CXCL9/10/11) driven immune cells
- →
-
Tumor-directed immune cells
Anti-angiogenesis
-
Chemokine-mediated
- →
-
Inhibited tumor blood vessel growth
HemaMax Exhibits Clear Advantages in Combination with Multiple SOC Therapies
Three Pillars of Cancer Therapeutics
Chemotherapy
Radiation
Immunotherapy
Current SOC Effects
Anti-tumor Efficacy
SOC therapies have anti-tumor efficacy that can be improved
Toxicity
Majority of therapies have limiting toxicity
HemaMax Benefits in CombinationHemaMax Benefits in Combination
Synergistically enhances efficacy by stimulating immune responses
Mitigates toxicity via hematopoietic effects